Dr. Martens (LON:DOCS) Issues Earnings Results

Dr. Martens (LON:DOCS) issued its quarterly earnings data on Tuesday. The company reported GBX 4.20 EPS for the quarter, Digital Look Earnings reports. The company had revenue of £764.90 million for the quarter. Dr. Martens had a return on equity of 4.40% and a net margin of 1.95%.

Here are the key takeaways from Dr. Martens’ conference call:

• Adjusted PBT rose 61% to £55.0 million reported, helped by stronger gross margin, tight cost control, and better revenue quality. The company also said net bank debt fell by £25 million, reinforcing balance sheet progress.
• Americas and APAC improved materially, with full-price DTC sales up 14% in the Americas and 15% in APAC. Management said this reflects a successful shift toward higher-quality revenue and less markdown dependence.
• EMEA remains the main weak spot, with DTC down amid a promotional market and weak consumer backdrop, especially in the U.K. and Germany. Management said completing the full-price pivot there is a key FY2027 focus and will likely create a near-term revenue headwind.
• Wholesale returned to growth for the first time since FY2023, supported by stronger order books for autumn/winter 2026. The company highlighted successful multi-year partnerships with retailers as a driver of that momentum.
• The brand and product pivot is gaining traction, with new families like Lowell, Buzz and Zebzag rising from 3% to 9% of pairs sold, while shoes grew 19% and bags 15%. Dr. Martens also said its organization is now streamlined and its new store formats are delivering higher average selling prices.

Dr. Martens Stock Up 3.8%

LON DOCS opened at GBX 66.76 on Tuesday. Dr. Martens has a twelve month low of GBX 53.05 and a twelve month high of GBX 100.87. The stock has a market cap of £645.71 million, a PE ratio of 39.27, a PEG ratio of 6.40 and a beta of 0.22. The firm has a 50-day simple moving average of GBX 63.94 and a 200 day simple moving average of GBX 71.49. The company has a debt-to-equity ratio of 120.66, a quick ratio of 1.13 and a current ratio of 2.18.

Insider Transactions at Dr. Martens

In other Dr. Martens news, insider Ije Nwokori sold 204,051 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of GBX 66, for a total value of £134,673.66. Insiders bought 930 shares of company stock worth $59,984 in the last 90 days. Insiders own 2.81% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on DOCS shares. Royal Bank Of Canada reissued a “sector perform” rating on shares of Dr. Martens in a research report on Tuesday, February 3rd. Berenberg Bank cut their price target on Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating for the company in a report on Tuesday. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of GBX 110.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.